nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC22A5—Crohn's disease	0.893	1	CbGaD
Methamphetamine—Amphetamine—SLC22A5—Crohn's disease	0.000356	0.475	CrCbGaD
Methamphetamine—Pseudoephedrine—TNF—Crohn's disease	0.000287	0.384	CrCbGaD
Methamphetamine—Nateglinide—ALB—Crohn's disease	0.000106	0.142	CrCbGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—GCKR—Crohn's disease	9.54e-05	0.000899	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	9.52e-05	0.000898	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—PTGER4—Crohn's disease	9.49e-05	0.000895	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—RASGRP1—Crohn's disease	9.34e-05	0.000881	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—MTMR3—Crohn's disease	9.2e-05	0.000867	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CCR6—Crohn's disease	9.14e-05	0.000862	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—MLN—Crohn's disease	9.13e-05	0.000862	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	8.91e-05	0.000841	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—ACKR2—Crohn's disease	8.75e-05	0.000825	CbGpPWpGaD
Methamphetamine—SLC22A3—SLC-mediated transmembrane transport—ALB—Crohn's disease	8.66e-05	0.000817	CbGpPWpGaD
Methamphetamine—SLC22A5—SLC-mediated transmembrane transport—ALB—Crohn's disease	8.64e-05	0.000815	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—PTGER4—Crohn's disease	8.61e-05	0.000812	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	8.58e-05	0.000809	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—UBE2D1—Crohn's disease	8.55e-05	0.000806	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—FADS1—Crohn's disease	8.47e-05	0.000799	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	8.43e-05	0.000795	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CCR9—Crohn's disease	8.34e-05	0.000787	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	8.33e-05	0.000785	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—F5—Crohn's disease	8.3e-05	0.000783	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—MLN—Crohn's disease	8.29e-05	0.000782	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—RIPK2—Crohn's disease	8.29e-05	0.000782	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	8.2e-05	0.000774	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL3—Crohn's disease	8.08e-05	0.000762	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—PTGER4—Crohn's disease	8.04e-05	0.000759	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PLA2G4F—Crohn's disease	8.02e-05	0.000757	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GPX4—Crohn's disease	7.93e-05	0.000748	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—IL1B—Crohn's disease	7.87e-05	0.000742	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—RASGRP1—Crohn's disease	7.82e-05	0.000737	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CCR9—Crohn's disease	7.79e-05	0.000735	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—GPR65—Crohn's disease	7.76e-05	0.000732	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GCKR—Crohn's disease	7.66e-05	0.000722	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCR9—Crohn's disease	7.58e-05	0.000715	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCR6—Crohn's disease	7.42e-05	0.0007	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—GPR65—Crohn's disease	7.25e-05	0.000683	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—FADS1—Crohn's disease	7.16e-05	0.000676	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—JAK2—Crohn's disease	7.09e-05	0.000669	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—SOCS1—Crohn's disease	7.08e-05	0.000668	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCR9—Crohn's disease	7.08e-05	0.000668	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—GPR65—Crohn's disease	7.04e-05	0.000664	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—Crohn's disease	6.97e-05	0.000657	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—MTMR3—Crohn's disease	6.82e-05	0.000643	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ACKR2—Crohn's disease	6.81e-05	0.000643	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	6.76e-05	0.000638	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—TYK2—Crohn's disease	6.75e-05	0.000637	CbGpPWpGaD
Methamphetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—Crohn's disease	6.74e-05	0.000636	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—ITGA4—Crohn's disease	6.73e-05	0.000634	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GPX4—Crohn's disease	6.71e-05	0.000633	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PLA2G4F—Crohn's disease	6.6e-05	0.000622	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—GPR65—Crohn's disease	6.58e-05	0.000621	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—IL3—Crohn's disease	6.56e-05	0.000619	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—PTGER4—Crohn's disease	6.53e-05	0.000616	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GCKR—Crohn's disease	6.48e-05	0.000611	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—CXCL8—Crohn's disease	6.47e-05	0.000611	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MLN—Crohn's disease	6.46e-05	0.000609	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—ALB—Crohn's disease	6.44e-05	0.000608	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—JAK2—Crohn's disease	6.44e-05	0.000608	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ACKR2—Crohn's disease	6.36e-05	0.0006	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—RASGRP1—Crohn's disease	6.34e-05	0.000598	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CCR9—Crohn's disease	6.33e-05	0.000597	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—ITGA4—Crohn's disease	6.28e-05	0.000593	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—IL3—Crohn's disease	6.13e-05	0.000578	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—SMAD3—Crohn's disease	6.11e-05	0.000577	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MLN—Crohn's disease	6.03e-05	0.000569	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—ALB—Crohn's disease	6.02e-05	0.000568	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	5.99e-05	0.000565	CbGpPWpGaD
Methamphetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—Crohn's disease	5.97e-05	0.000563	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—RASGRP1—Crohn's disease	5.93e-05	0.000559	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TAGAP—Crohn's disease	5.91e-05	0.000557	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—GPR65—Crohn's disease	5.89e-05	0.000555	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CXCL8—Crohn's disease	5.88e-05	0.000554	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCR9—Crohn's disease	5.75e-05	0.000542	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—TNF—Crohn's disease	5.71e-05	0.000539	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL2RA—Crohn's disease	5.66e-05	0.000534	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—Crohn's disease	5.62e-05	0.00053	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—MTMR3—Crohn's disease	5.61e-05	0.000529	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	5.6e-05	0.000528	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CCR6—Crohn's disease	5.53e-05	0.000521	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TAGAP—Crohn's disease	5.52e-05	0.00052	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PLA2G4F—Crohn's disease	5.36e-05	0.000506	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—GPR65—Crohn's disease	5.34e-05	0.000504	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—FADS1—Crohn's disease	5.31e-05	0.000501	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—CXCL8—Crohn's disease	5.21e-05	0.000491	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ACKR2—Crohn's disease	5.17e-05	0.000488	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CCR6—Crohn's disease	5.16e-05	0.000487	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RSPO3—Crohn's disease	5.16e-05	0.000487	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—ITGA4—Crohn's disease	5.1e-05	0.000481	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—ALB—Crohn's disease	5.09e-05	0.00048	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCR6—Crohn's disease	5.02e-05	0.000473	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IL3—Crohn's disease	4.98e-05	0.000469	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GPX4—Crohn's disease	4.98e-05	0.000469	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MLN—Crohn's disease	4.9e-05	0.000462	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SEL1L—Crohn's disease	4.89e-05	0.000462	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—ALB—Crohn's disease	4.89e-05	0.000461	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—PTGER4—Crohn's disease	4.87e-05	0.000459	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CXCL8—Crohn's disease	4.86e-05	0.000459	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RSPO3—Crohn's disease	4.82e-05	0.000455	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—RASGRP1—Crohn's disease	4.81e-05	0.000454	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GCKR—Crohn's disease	4.81e-05	0.000453	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCR6—Crohn's disease	4.69e-05	0.000442	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—IL6—Crohn's disease	4.61e-05	0.000435	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—IL2RA—Crohn's disease	4.59e-05	0.000433	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—IL6—Crohn's disease	4.59e-05	0.000433	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SEL1L—Crohn's disease	4.57e-05	0.000431	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MTMR3—Crohn's disease	4.56e-05	0.00043	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—PTGER4—Crohn's disease	4.55e-05	0.000429	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	4.55e-05	0.000429	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TAGAP—Crohn's disease	4.48e-05	0.000423	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCR9—Crohn's disease	4.48e-05	0.000422	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PTGER4—Crohn's disease	4.42e-05	0.000417	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—ALB—Crohn's disease	4.4e-05	0.000415	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—ALB—Crohn's disease	4.39e-05	0.000414	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—FADS1—Crohn's disease	4.37e-05	0.000412	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—IL2RA—Crohn's disease	4.29e-05	0.000405	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CCR6—Crohn's disease	4.19e-05	0.000396	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCR9—Crohn's disease	4.18e-05	0.000394	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—GPR65—Crohn's disease	4.16e-05	0.000393	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—IL3—Crohn's disease	4.14e-05	0.000391	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	4.14e-05	0.00039	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PTGER4—Crohn's disease	4.13e-05	0.000389	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GPX4—Crohn's disease	4.09e-05	0.000386	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—RASGRP1—Crohn's disease	4.01e-05	0.000378	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TYK2—Crohn's disease	3.99e-05	0.000376	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GCKR—Crohn's disease	3.95e-05	0.000373	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CXCL8—Crohn's disease	3.95e-05	0.000373	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RSPO3—Crohn's disease	3.92e-05	0.000369	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GPR65—Crohn's disease	3.89e-05	0.000367	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—IL3—Crohn's disease	3.87e-05	0.000365	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	3.87e-05	0.000365	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCR6—Crohn's disease	3.81e-05	0.000359	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—JAK2—Crohn's disease	3.8e-05	0.000359	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL3—Crohn's disease	3.76e-05	0.000355	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—RASGRP1—Crohn's disease	3.74e-05	0.000353	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SEL1L—Crohn's disease	3.71e-05	0.00035	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PTGER4—Crohn's disease	3.69e-05	0.000348	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—RASGRP1—Crohn's disease	3.64e-05	0.000343	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—FADS1—Crohn's disease	3.55e-05	0.000335	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL3—Crohn's disease	3.52e-05	0.000332	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PLA2G4F—Crohn's disease	3.49e-05	0.000329	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IL2RA—Crohn's disease	3.49e-05	0.000329	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CXCL8—Crohn's disease	3.47e-05	0.000328	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—Crohn's disease	3.43e-05	0.000323	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—RASGRP1—Crohn's disease	3.4e-05	0.000321	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCR9—Crohn's disease	3.4e-05	0.00032	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PTGER4—Crohn's disease	3.35e-05	0.000316	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GPX4—Crohn's disease	3.32e-05	0.000314	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—ALB—Crohn's disease	3.32e-05	0.000313	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—IL6—Crohn's disease	3.3e-05	0.000311	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GCKR—Crohn's disease	3.21e-05	0.000303	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GPR65—Crohn's disease	3.16e-05	0.000298	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CXCL8—Crohn's disease	3.15e-05	0.000297	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—IL3—Crohn's disease	3.14e-05	0.000297	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	3.14e-05	0.000296	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—ALB—Crohn's disease	3.1e-05	0.000293	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—JAK2—Crohn's disease	3.09e-05	0.000291	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—RASGRP1—Crohn's disease	3.04e-05	0.000287	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—Crohn's disease	3.03e-05	0.000286	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTMR3—Crohn's disease	2.97e-05	0.00028	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCR6—Crohn's disease	2.97e-05	0.00028	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CXCL8—Crohn's disease	2.94e-05	0.000278	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—IL2RA—Crohn's disease	2.9e-05	0.000274	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—JAK2—Crohn's disease	2.88e-05	0.000272	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL3—Crohn's disease	2.86e-05	0.000269	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—STAT3—Crohn's disease	2.79e-05	0.000263	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCR6—Crohn's disease	2.77e-05	0.000261	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—RASGRP1—Crohn's disease	2.76e-05	0.000261	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—IL2RA—Crohn's disease	2.71e-05	0.000256	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RBX1—Crohn's disease	2.68e-05	0.000253	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL2RA—Crohn's disease	2.64e-05	0.000249	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PTGER4—Crohn's disease	2.61e-05	0.000246	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—ALB—Crohn's disease	2.52e-05	0.000238	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RBX1—Crohn's disease	2.5e-05	0.000236	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL2RA—Crohn's disease	2.46e-05	0.000232	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PTGER4—Crohn's disease	2.44e-05	0.00023	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—ALB—Crohn's disease	2.44e-05	0.00023	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CXCL8—Crohn's disease	2.39e-05	0.000226	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—UBE2D1—Crohn's disease	2.35e-05	0.000222	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—JAK2—Crohn's disease	2.34e-05	0.000221	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—FADS1—Crohn's disease	2.31e-05	0.000218	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RIPK2—Crohn's disease	2.28e-05	0.000215	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCR6—Crohn's disease	2.25e-05	0.000212	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL3—Crohn's disease	2.22e-05	0.00021	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—IL2RA—Crohn's disease	2.2e-05	0.000208	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—UBE2D1—Crohn's disease	2.2e-05	0.000207	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GPX4—Crohn's disease	2.17e-05	0.000204	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RASGRP1—Crohn's disease	2.15e-05	0.000203	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PTGS2—Crohn's disease	2.13e-05	0.000201	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RIPK2—Crohn's disease	2.13e-05	0.000201	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GCKR—Crohn's disease	2.09e-05	0.000197	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL3—Crohn's disease	2.08e-05	0.000196	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—ALB—Crohn's disease	2.06e-05	0.000195	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RBX1—Crohn's disease	2.03e-05	0.000192	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RASGRP1—Crohn's disease	2.01e-05	0.000189	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL2RA—Crohn's disease	2e-05	0.000189	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PTGER4—Crohn's disease	1.98e-05	0.000187	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—JAK2—Crohn's disease	1.95e-05	0.000184	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL6—Crohn's disease	1.95e-05	0.000184	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SOCS1—Crohn's disease	1.95e-05	0.000184	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—TYK2—Crohn's disease	1.86e-05	0.000175	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—JAK2—Crohn's disease	1.82e-05	0.000172	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SOCS1—Crohn's disease	1.82e-05	0.000172	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PTGS2—Crohn's disease	1.8e-05	0.00017	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—UBE2D1—Crohn's disease	1.78e-05	0.000168	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCL8—Crohn's disease	1.78e-05	0.000168	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—JAK2—Crohn's disease	1.77e-05	0.000167	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—TYK2—Crohn's disease	1.74e-05	0.000164	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RIPK2—Crohn's disease	1.73e-05	0.000163	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL3—Crohn's disease	1.69e-05	0.000159	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SMAD3—Crohn's disease	1.68e-05	0.000159	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCL8—Crohn's disease	1.66e-05	0.000157	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—JAK2—Crohn's disease	1.66e-05	0.000156	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RASGRP1—Crohn's disease	1.63e-05	0.000154	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCL8—Crohn's disease	1.62e-05	0.000153	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SMAD3—Crohn's disease	1.57e-05	0.000148	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL2RA—Crohn's disease	1.56e-05	0.000147	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ALB—Crohn's disease	1.53e-05	0.000144	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCL8—Crohn's disease	1.51e-05	0.000143	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—JAK2—Crohn's disease	1.48e-05	0.00014	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SOCS1—Crohn's disease	1.48e-05	0.000139	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL2RA—Crohn's disease	1.45e-05	0.000137	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—TYK2—Crohn's disease	1.41e-05	0.000133	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL8—Crohn's disease	1.35e-05	0.000127	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—JAK2—Crohn's disease	1.34e-05	0.000127	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTGS2—Crohn's disease	1.34e-05	0.000126	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SMAD3—Crohn's disease	1.28e-05	0.00012	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ALB—Crohn's disease	1.26e-05	0.000119	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL8—Crohn's disease	1.23e-05	0.000116	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL2RA—Crohn's disease	1.18e-05	0.000111	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTGS2—Crohn's disease	1.1e-05	0.000104	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TYK2—Crohn's disease	1.1e-05	0.000104	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—JAK2—Crohn's disease	1.05e-05	9.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TYK2—Crohn's disease	1.03e-05	9.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ALB—Crohn's disease	1.02e-05	9.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—JAK2—Crohn's disease	9.78e-06	9.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL8—Crohn's disease	9.55e-06	9.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—Crohn's disease	9.09e-06	8.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTGS2—Crohn's disease	8.94e-06	8.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL8—Crohn's disease	8.93e-06	8.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—Crohn's disease	8.49e-06	8.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TYK2—Crohn's disease	8.33e-06	7.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—JAK2—Crohn's disease	7.94e-06	7.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—STAT3—Crohn's disease	7.68e-06	7.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL8—Crohn's disease	7.25e-06	6.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—STAT3—Crohn's disease	7.18e-06	6.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—Crohn's disease	6.89e-06	6.5e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ALB—Crohn's disease	6.66e-06	6.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STAT3—Crohn's disease	5.83e-06	5.5e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTGS2—Crohn's disease	5.83e-06	5.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—Crohn's disease	5.37e-06	5.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—Crohn's disease	5.01e-06	4.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—Crohn's disease	4.07e-06	3.84e-05	CbGpPWpGaD
